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Research
Exposure to environmental endocrine disrup-
tors is a potential risk factor for humans.
With the increasing use of ultraviolet (UV)
filters in sunscreens and cosmetics and as
additives in plastics and household products,
their possible environmental impact deserves
consideration. UV filters may be directly
introduced into surface waters during swim-
ming or they may enter wastewater from
households or industry. There is good evi-
dence that pharmaceuticals and ingredients of
personal care products can spread into the
biosphere and reach the food chain: UV ﬁlters
are present in water downstream of sewage
treatment plants (Kupper et al. 2006;
Plagellat et al. 2006) in surface waters (Buser
et al. 2005, 2006), and they bioaccumulate in
fish (Balmer et al. 2005, Buser et al. 2006;
Nagtegaal et al. 1997). In a recent monitor-
ing study, UV filters were found in 75% of
human milk samples (Schlumpf et al. 2008),
indicating potential exposure of newborns. 
Certain UV filters have been shown to
exhibit estrogenic activity in both in vitro and
in vivo assays (Schlumpf et al. 2001, 2004a),
and they have also shown developmental toxic-
ity (Durrer et al. 2005, 2007; Maerkel et al.
2007). In vitro studies showed that 4-methyl-
benzylidene camphor (4-MBC) and 3-benzyli-
dene camphor (3-BC), are estrogen receptor
(ER)-β ligands (Schlumpf et al. 2004a), but
they are also active in ER-α–typical in vivo
tests such as the uterotrophic assay (Schlumpf
et al. 2001, 2004a).
Many endocrine-active xenobiotics affect
normal cellular and developmental processes
in animal models, with the prostate being one
sensitive target (Timms et al. 2005; vom Saal
et al. 1997). These effects can be seen in both
the juvenile and adult stages of growth in the
prostate. Developmental exposure to 4-MBC
and 3-BC affects prostate weight and estrogen
target gene expression, in addition to effects
on other targets such as brain, uterus, and
thyroid (Durrer et al. 2005, 2007; Maerkel
et al. 2007; Schlumpf et al. 2004b).
Although fetal prostate development is pri-
marily regulated by androgens (Siiteri and
Wilson 1974), addition of exogenous estrogens
during critical periods of growth has the
potential to alter the development of the
prostate (Richter et al. 2007; Timms et al.
2005; vom Saal et al. 1997). Growth responses
to estrogen and estrogen mimics are variable
and depend on dose and timing of treatment.
Low-level exposure to estrogenic compounds
administered during fetal development results
in a region-specific proliferative growth
response (Timms et al. 2005; vom Saal et al.
1997). Conversely, postnatal treatment with
higher doses of estrogen has an inhibitory
effect on growth (Huang et al. 2005; Prins and
Korach 2007; Timms et al. 2005).
In the present study we investigated the
effects of 4-MBC and 3-BC on the developing
prostate in the fetal rat. This experiment was
designed, as previously described (Durrer et al.
2005, 2007; Maerkel et al. 2007), to examine
the effects caused by systemic, low-dose expo-
sure throughout in utero development. We
administered 4-MBC and 3-BC at two dose
levels, corresponding to previously published
classical lowest observed adverse effect level
(LOAEL) and classical no observed adverse
effect level (NOAEL)/molecular LOAEL,
respectively (Durrer et al. 2005, 2007;
Maerkel et al. 2007; Schlumpf et al. 2008).
Our data support the hypothesis that exposure
to low doses of environmentally relevant
endocrine disruptors during early prostate
development alters normal growth patterns
and extends the range of active chemicals to
UV ﬁlters used in cosmetics. 
Materials and Methods
Chemicals. We purchased 4-MBC (Eusolex
6300, CAS no. 36861-47-9, molecular weight
254.37, purity 99.7–99.9%) from Merck
Schweiz (Dietikon, Switzerland) and 3-BC
(Unisol-S22, CAS no. 15087–24–8, molecu-
lar weight 240.0, purity > 97.0 %) from
Induchem AG (Volketswil, Switzerland).
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BACKGROUND AND OBJECTIVES: Exposure to environmental endocrine disruptors is a potential risk
factor for humans. Many of these chemicals have been shown to exhibit disruption of normal cellu-
lar and developmental processes in animal models. Ultraviolet (UV) ﬁlters used as sunscreens in
cosmetics have previously been shown to exhibit estrogenic activity in in vitro and in vivo assays.
We examined the effects of two UV ﬁlters, 4-methylbenzylidene camphor (4-MBC) and 3-benzyli-
dene camphor (3-BC), in the developing prostate of the fetal rat. 
METHODS: Pregnant Long Evans rats were fed diets containing doses of 4-MBC and 3-BC that
resulted in average daily intakes of these chemicals corresponding to the lowest observed adverse
effects level (LOAEL) and the no observed adverse effects level (NOAEL) doses in prior develop-
mental toxicity studies. Using digital photographs of serial sections from postnatal day 1 animals,
we identiﬁed, contoured, and aligned the epithelial ducts from speciﬁc regions of the developing
prostate, plus the accessory sex glands and calculated the total volume for each region from three-
dimensional, surface-rendered models. 
RESULTS: Fetal exposure to 4-MBC (7.0 mg/kg body weight/day) resulted in a signiﬁcant increase
(p < 0.05) in tissue volume in the prostate and accessory sex glands. Treated males exhibited a 62%
increase in the number of ducts in the caudal dorsal prostate. Increased distal branching morpho-
genesis appears to be a consequence of exposure in the ventral region, resulting in a 106% increase
in ductal volume.
CONCLUSIONS: 4-MBC exposure during development of the male reproductive accessory sex glands
exhibited classical growth effects associated with estrogenic endocrine disruptors. The different
regional responses suggest that the two developmental processes of ductal outgrowth and branching
morphogenesis are affected independently by exposure to the environmental chemicals.
KEY WORDS: endocrine disruptors, 4-methylbenzylidene camphor (4-MBC), prostate development,
UV filters. Environ Health Perspect 116:867–872 (2008). doi:10.1289/ehp.10983 available via
http://dx.doi.org/ [Online 25 March 2008]Animals. Long Evans rats were purchased
from Centre d’Elevage R. Janvier (Le Genest-
St. Isle, France) and shipped to the animal facil-
ity of the Department of Physiology, Medical
School, Complutense University, Madrid,
Spain. The animals were kept under controlled
conditions with free access to water and a soy-
free rat chow (Nutreco, Toledo, Spain). Animal
experiments followed the European Union
normative (86/609/EEC; European Union
1986) and were approved by the Institutional
Animal Care Committee of Complutense
University. All animals were treated humanely
and with regard for alleviation of suffering.
4-MBC or 3-BC treatment. Chow was
prepared by adding 4-MBC and 3-BC to the
soy-free rat chow (Nutreco). 4-MBC was
added at concentrations of 10 and 100 mg/kg
chow, yielding an average daily intake of
0.7 and 7 mg/kg body weight (bw)/day, and
3-BC was added at concentrations of 1 and
3.3 mg/kg chow, yielding a dose of 0.07 and
0.24 mg/kg bw/day. Control chow consisted
of the same matrix.
This study was part of a larger study
involving dissection of brain and reproductive
organs at different postnatal stages and was
designed to mimic exposure through the food
chain during prenatal and early postnatal life.
Males and females of the parent generation
(F0; 5–6 weeks of age) were fed for at least
10 weeks before mating (including one
spermatogenic cycle) with chow containing
4-MBC (0.7 or 7 mg/kg bw/day) or 3-BC
(0.07 or 0.24 mg/kg bw/day) or control chow.
Treatment continued throughout pregnancy
and lactation. Rats were allowed to mate
overnight, and pregnant (sperm-positive)
females were kept in groups of two and sepa-
rated 1 day before parturition.
Birth and tissue preparation. Around
expected birth term [gestational day (GD) 23;
GD1 = 24 hr after mating], we observed preg-
nant dams at least three times during the light
period for signs of birth. The day of birth was
defined as postnatal day (PND) 1 (GD23).
The dam and litter remained undisturbed
until all the offspring had been born. Then
one or two of the male offspring were gently
taken out of the cage, wrapped in warm paper
towels, and kept under red light (32 ± 1°C)
for 1–2 min before being anesthetized by
cooling the body until motionlessness in
crushed ice. After decapitating the rats on a
precooled plate (ice), the lower part of the
body was sectioned just below the level of the
umbilical cord using a razor blade and imme-
diately immersed into 4% buffered formalde-
hyde for 24 hr and stored in 70% ethanol.
One offspring per litter was transferred to the
University of South Dakota for final tissue
preparation, three-dimensional (3-D) recon-
struction, and morphometric analysis.
3-D reconstruction. The urogenital sinus
(UGS) and developing prostate were processed
as described previously (Timms et al. 2005).
Briefly, serial tissue sections (6 µm) were
stained with hematoxylin and eosin and photo-
graphed with an Olympus DP70 digital cam-
era fitted to an Olympus BX60 microscope
(Leeds Precision Instruments, Minneapolis,
MN, USA). Histological images of the devel-
oping prostate buds and associated structures
were traced, contoured, and realigned as sur-
face-rendered 3-D models using Winsurf
reconstruction software (University of Hawaii
at Manoa, Honolulu, HI, USA). To compare
and examine the effects of the treatments with
untreated control animals, we performed
morphometric and volumetric analyses. 
Hofkamp et al.
868 VOLUME 116 | NUMBER 7 | July 2008 • Environmental Health Perspectives
Figure 1. 3-D serial section reconstruction of accessory reproductive organs in male PND1 Long Evans rats
after systemic and developmental in utero exposure to 7.0 mg/kg bw 4-MBC. Abbreviations: DT, distal tip;
PD, proximal duct, VMP, ventral mesenchymal pad. (A) Right lateral view of the surface-rendered anatomi-
cal reconstruction of the UGS and ASG structures in a control male. Individual structures are identiﬁed by
color. (B) Reconstruction of the right lateral and cranial views of the UGS from a 4-MBC–treated male and
untreated control male illustrating the signiﬁcant regional growth differences in ducts of the caudal dorsal
prostate and branching morphogenesis development in the ventral region. (C) Additional anatomical views
of the prostatic ducts of a control male and a 4-MBC treated male showing the regional growth patterns.
(D) Representative histological views of distal-tip budding in the ventral prostate region. Initial bifurcation is
the primary feature of the control male, whereas extensive secondary branching morphogenesis has
occurred in the 4-MBC–treated male (stained with hematoxylin and eosin; bar = 100 µm). (E) Anatomical
view of the UGS, ventral ducts, and VMP showing that the distal tips of the ducts in the control male have
made initial contact with the VMP. In the 4-MBC–treated male, the distal tips have penetrated the mes-
enchymal tissue and undergone later stages of branching morphogenesis. (F) Lateral and dorsal view of the
UGS. Shape of the UGS (gray arrow) and bladder neck region of the urethra (black arrow) are changed in
the 4-MBC–treated male. 
A
B C
D E F
0.25 mm
Control
4-MBC
(7.0 mg/kg)
Right lateral view Cranial view Cranial view Dorsal view Ventral view
Control
4-MBC
(7.0 mg/kg)
Right lateral view Cranial view Ventral view Right lateral view Dorsal view
Ventral prostate
Ventral mesenchyme
Dorsal prostate (caudal)
Dorsal prostate (cranial)
Lateral prostate
CG
SV
Vas deferens
Urethra
3-D reconstructionStatistics. All volumetric and ductal
development data, with the exception of the
mesenchymal study, were analyzed using one-
way analysis of variance, followed by a
Dunnett’s post hoc test, using StatMost for
Windows software (DataMost Corporation,
Salt Lake City, UT, USA). We analyzed the
mesenchyme volume data using the Mann-
Whitney test. The conﬁdence level for reject-
ing the null hypothesis was p < 0.05. Data are
presented as mean ± SE. For all groups, n =4 .
All samples were blinded to ensure the
absence of bias.
Results
Accessory sex glands. Figure 1A illustrates the
components of the accessory sex glands
(ASGs) that were examined individually or as
anatomically related groups. The ASGs,
including the seminal vesicles (SV), coagulat-
ing gland (CG), and the dorsal, lateral, and
ventral prostate (DLVP) as a whole, were sig-
niﬁcantly sensitive to the effects of 4-MBC at
the 7.0-mg/kg bw dose (Figure 2). All of the
subsequent findings pertain to the effects of
exposure to this dose of 4-MBC compared
with untreated control males. No signiﬁcant
effects were observed under any 3-BC treat-
ments or the 0.7-mg/kg bw dose of 4-MBC.
We observed a 69% overall increase in the
ASG volume (p < 0.005), compared with
untreated controls. Treatment significantly
increased the volume of the SV by 66%
(p < 0.001), the CG by 68% (p < 0.01), and
the developing prostate (DLVP) by 69%
(p < 0.01; Figure 2). We also observed a nar-
rowing of the urethra at the neck of the blad-
der in this treatment group (Figure 1F). This
feature is consistent with a prior study of
endocrine disruptor exposure (Timms et al.
2005).
Dorsolateral prostate. A detailed 3-D
reconstruction of a speciﬁc group of ducts in
the developing dorsolateral prostate revealed
that the most sensitive region to 4-MBC was
the caudal area of dorsal prostatic ducts,
which increased in volume by 62% (p < 0.05;
Figures 1A,C and 2). In contrast, the cranial
portion of the dorsal prostate and the lateral
prostate did not exhibit any significant
growth response to treatment.
Ventral prostate and ventral mesen-
chymal pad (VMP). We observed a signiﬁcant
increase in prostatic duct volume (106%;
p < 0.01) in the ventral region of the prostate
(Figure 3). The 3-D reconstruction analysis
also revealed a more pronounced develop-
ment of distal tip branching morphogenesis
(Figure 1B,C,D). The VMP (Timms et al.
1994), which is intimately involved in distal
tip branching, was also increased in volume
by 64% (p < 0.05; Figure 1F).
Prostatic duct development. The number
of prostate ducts developing from the UGS
has been shown to increase after prenatal
estrogen treatment (Timms et al. 2005; vom
Saal et al. 1997). In the present study we
observed a similar increase in the number of
dorsal ducts, particularly in the caudal region
of the UGS (62%, p < 0.05; Figure 4).
However, despite an increased ductal volume
in the ventral prostate, there was no increase
in the number of ducts growing from the
ventral wall of the UGS (Figures 1C and 4).
Discussion
Normal prostate development is dependent on
androgens (Siiteri and Wilson 1974). However,
UV filters and fetal prostate development
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Figure 3. Comparative volume analyses of speciﬁc regions of the developing prostate in PND1 males after
prenatal exposure to various doses of UV ﬁlter compounds. Signiﬁcant effects were observed only in the dor-
sal and ventral regions of the 7.0 mg/kg bw–treated males. Values shown are mean ± SE (n = 4 for all groups). 
*p < 0.05, and **p < 0.01 compared with control males. 
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Figure 2. Comparative volume analyses of individual and combined regions of the ASGs in PND1 males
after prenatal exposure to various doses of UV ﬁlter compounds. Signiﬁcant effects were observed only in
the 7.0 mg/kg bw–treated males. Values shown are mean ± SE (n = 4 for all groups). 
*p < 0.05, **p < 0.01, #p < 0.005, and ##p < 0.001 compared with control males. 
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Figure 4. Effects of prenatal exposure to UV filter compounds on prostate duct development in PND1
males. A significant increase in the number of developing ducts was observed in the combined dorso-
lateral prostate region (DLP). This increase was due speciﬁcally to an increase in the number of ducts in
the caudal region of the dorsal prostate. Values shown are mean ± SE (n = 4 for all groups). 
*p < 0.05 compared with control males. 
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*exposure to abnormally high levels of estrogen
during the critical period of development has
the potential to alter growth-control mecha-
nisms (Huang et al. 2004; Prins et al. 2006).
In contrast, low-level exposure to estrogen, or
estrogen mimics, during the same developmen-
tal period has been shown to alter the regula-
tion of androgen receptors (AR) and ERs
(Richter et al. 2007; vom Saal et al. 1997). A
shift in receptor density predisposes the
prostate for altered hormonal regulation (Wu
et al. 2007). Along with changes in receptor
regulation, endocrine-disrupting compounds
inhibit the production of phosphodiesterase
and increase transcription of the aromatase
gene CYP19 (cytochrome P450) under promo-
tion of aromatase promoter II in the prostate
(Fan et al. 2007). This aromatization of testos-
terone into localized free estrogen can further
destabilize the androgen-regulated growth of
prostatic epithelium.
The results of the present study support
the classification of 4-MBC as an endocrine
disruptor (Schlumpf et al. 2001, 2004b;
Schreurs et al. 2005). The doses of 7 and
0.7 mg/kg bw/day examined in this study
represent the LOAEL and NOAEL, respec-
tively, for classical toxicity end points in
extended one generation–type studies, such as
puberty in males, adult ventral prostate
weight, and female sexual behavior. Changes
in estrogen-regulated gene expression in adult
male and female offspring were still present at
the lower dose, 0.7 mg/kg bw/day (Durrer
et al. 2005, 2007; Maerkel et al. 2007;
Schlumpf et al. 2008). In chronic (90-day)
studies on adult ovariectomized rats, interac-
tions of 4-MBC with estrogenic mechanisms
have been observed in additional targets such
as luteinizing hormone, bone, adipose tissue,
and leptin. However, these effects were seen at
higher doses than those used in our develop-
mental toxicity studies (Seidlova-Wuttke et al.
2006a, 2006b).
Exposure of neonates to the chemicals has
been assessed by determining 4-MBC and
3-BC concentrations in rat milk (Schlumpf
et al. 2008). The effective dose of 7 mg/kg
bw/day yields a 4-MBC concentration of
209 ng/g lipid, which is 11 times the highest
value found thus far in our ongoing monitor-
ing study on human milk (19 ng/g lipid).
This level would be considered within the risk
factor zone for human safety.
The prostate is very sensitive to deviations
from homeostatic androgen-to-estrogen
ratios. Compounds that mimic the effects of
estrogen have the potential to alter the
development of the prostate by inducing
morphologic changes (Prins 1992; Timms et
al. 2005; vom Saal et al. 1997). These effects
follow an inverted U-curve pattern, which at
low doses cause a proliferative response
(Timms et al. 2005) and at higher doses cause
an inhibitory effect (vom Saal et al. 1997). In
the present study, using low-dose in utero sys-
temic exposure, we observed proliferative
effects similar to those found in other low-
dose exposure experiments (Timms et al.
2005; vom Saal et al. 1997).
4-MBC is a preferential ER-β ligand with
limited ER-α binding capacity in vitro
(Mueller et al. 2003; Schlumpf et al. 2004a),
but it also exerts estrogenic effects in vivo that
depend on ER-α, such as the uterotrophic
response in immature rats (Schlumpf et al.
2001, 2004a). This might be due to an estro-
genic metabolite whose activity has not been
characterized in detail (Völkel et al. 2006).
Thus, in vivo effects of this UV ﬁlter probably
represent a combination of ER-β– and ER-α–
mediated actions. Reporter gene assays on AR
yielded conflicting results for both 4-MBC
and 3-BC, including complete absence of ago-
nistic or antagonistic activity, in contrast to
some other UV ﬁlters (Ma et al. 2003), as well
as the presence of weak antiandrogenic activity
(Schreurs et al. 2005). So far, interactions with
androgenic mechanisms have not been tested
in acute in vivo models, but estrogenic activity
of 4-MBC and 3-BC has been confirmed in
the uterotrophic assay (Schlumpf et al. 2001,
2004a; Tinwell et al. 2002). Thus, actions on
ER seem to provide the most straightforward
explanation for the effects of 4-MBC on the
neonatal prostate. It is interesting that the
dose of 7 mg/kg bw/day 4-MBC enhances
prostate growth during the neonatal period
but causes a decrease in the weight of ventral
and dorsolateral prostate lobes and a reduced
expression of AR and ER-α at mRNA and
protein levels in chronically exposed adult off-
spring (Durrer et al. 2007; Schlumpf et al.
2008). Because the adult rats had been contin-
uously exposed during prenatal and postnatal
life, it seems possible that the different effects
are due to a switch in the relative importance
of the actions on ER-α and ER-β. The conse-
quences of this switch, with regard to potential
lifelong exposure, should be kept in mind
(Durrer et al. 2007; Schlumpf et al. 2008).
The lack of effect of 3-BC was surprising
because 3-BC and 4-MBC behave very simi-
larly in acute tests for estrogenic activity
(Schlumpf et al. 2001, 2004a). The 3-BC doses
we used affect gene expression in the early post-
natal uterus (Schlumpf et al. 2008), but they
may be too low to inﬂuence prostate growth.
However, in spite of similarities in chemical
structure and acute actions, the effect patterns
of 4-MBC and 3-BC differ in developmentally
exposed adult animals (Durrer et al. 2007;
Schlumpf et al. 2008). Ventral prostate weight
was reduced by 4-MBC in a dose-dependent
manner, but it was unaffected by 3-BC except
for the lowest dose used in that study
(0.24 mg/kg bw/day). Also, effects of 3-BC
and 4-MBC on AR and ER-α in prostate of
adult offspring were opposite at mRNA and
protein levels (Durrer et al. 2007; Schlumpf
et al. 2008). Thus, it seems conceivable that
effects of two compounds on the neonatal
prostate may differ, even though the reason for
this difference remains unknown.
The different growth effects within spe-
ciﬁc regions of the prostate substantiate earlier
studies. Previously, the combined dorsal and
lateral regions were grouped as the dorso-
lateral prostate (Prins and Korach 2007;
Timms et al. 2005). Using our 3-D recon-
struction program, Winsurf, we were able to
further differentiate the dorsolateral prostate
into its dorsal and lateral components. In
addition, the dorsal prostate was divided into
two distinct regions separate from the lateral
prostate (Figure 1A). The effects seen in these
areas were unique. We observed no signiﬁcant
volumetric changes in the lateral prostate or
in the cranial region of the dorsal prostate
ducts (Timms et al. 1994), a region described
as LP1 by Hayashi et al. (1991). In the caudal
region of the dorsal prostate ducts there was
a significant increase in volume, which was
primarily due to an increase in the number
of ducts developing from the UGS wall
(Figure 1C). In the normal rodent prostate
the number of ducts that develop from the
wall of the UGS is fairly constant (Timms
et al. 2005). Any additional ducts formed
then become part of the adult glandular struc-
ture and have the potential to increase the
prevalence of disorders later in life (Risbridger
et al. 2005).
An important component of ductal for-
mation is the surrounding mesenchymal tis-
sue into which the prostatic buds grow
(Cunha and Cooke 2004). Growth factors
produced by this tissue play an important role
in the process of branching morphogenesis
and early glandular development (Thomson
et al. 2002). Each region of the prostate and
the adjacent Wolffian duct system contain
their own respective mesenchyme (Hannema
and Hughes 2007; Thomson et al. 2002;
Timms et al. 1994, 1995, 1999). Branching
Hofkamp et al.
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Figure 5. Effect of prenatal exposure to 4-MBC
(7.0 mg/kg bw) on VMP tissue volume in PND1 males.
Values shown are mean ± SE (n = 4 for all groups). 
*p < 0.05 compared with control males. 
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into their local mesenchyme (Timms et al.
1995; vom Saal et al. 1997). Branching mor-
phogenesis is the process by which the distal
tips of immature prostatic ducts begin bifur-
cation and form the complex glandular archi-
tecture commonly seen in the adult prostate
(Figure 1D). The increased ductal volume in
the ventral prostate that resulted from an
increase in the distal tip volume was a very
different response to that seen in the dorsal
ducts, where the increased ductal volume was
primarily due to an increase in the number of
ducts. These distinct regional differences sug-
gest that exposure to endocrine disruptors
during fetal development can affect specific
developmental events, such as duct formation
and branching morphogenesis. Furthermore,
this suggests that environmental estrogens can
exert their effects on distinct mechanisms
within the same tissue. Because the VMP
(Timms et al. 1994) is an important growth-
inducing tissue in ventral prostate develop-
ment (Thomson et al. 2002), we examined
the volumetric parameter and found a signiﬁ-
cant increase in volume after 4-MBC expo-
sure (Figures 1E and 5). The VMP is present
before the onset of ductal outgrowth (Timms
et al. 1994, 1995), and it is possible that the
increased volume may have been established
before ductal development in response to
4-MBC exposure. The increase in the number
of caudal ducts in the dorsal prostate may
reﬂect a growth effect of exposure via epithe-
lial–mesenchymal interactions in the peri-
urethral mesenchyme surrounding the
urothelium. This mesenchyme is distinct
from the VMP (Timms et al. 1995) and is
likely to express different growth factors.
The recent evidence regarding the effects
of 4-MBC on the developing fetus has placed
this widely used UV filter in the category of
known endocrine-disrupting compounds
(Schlumpf et al. 2008; Søeborg et al. 2007).
The effects of this compound on the develop-
ing prostate are strikingly similar to those of
another known estrogen-mimicking com-
pound, bisphenol A (BPA; Timms et al.
2005). UV filters, including 4-MBC, bio-
accumulate in the environment (Balmer et al.
2005; Buser et al. 2006). They were found in
75% of human milk samples (Schlumpf et al.
2008), indicating potential transfer of these
chemicals to the newborn infant. Human
exposure stems mainly from the use of cos-
metics, but exposure may also originate from
the food chain. Both the European Union
[Scientiﬁc Committee on Consumer Products
(SCCP) 2006a, 2006b] and the U.S. Food
and Drug Administration (2003) are cur-
rently reviewing data on 4-MBC, also known
as enzacamene, Parsol 5000 (Roche 2000),
and Eusolex 6300 (Merck 2005). The differ-
ent responses observed in the present study
suggest that the two developmental processes
of ductal outgrowth and branching morpho-
genesis are affected independently by exposure
to environmental chemicals at critical periods
of UGS development. Our ﬁndings of prena-
tal growth effects, plus previous reports that
these compounds are found in the environ-
ment, justify additional studies to determine
the mechanisms underlying the characteristic
growth responses during fetal development.
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